162. 類天疱瘡（後天性表皮水疱症を含む。） ［臨床試験数：49，薬物数：72（DrugBank：35），標的遺伝子数：23，標的パスウェイ数：118］
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04128176 | November 25, 2019 | 28 October 2019 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab combined with Omalizumab | University of California, Davis | Not recruiting | 18 Years | 90 Years | All | 15 | Phase 3 | United States | |
| 2 | NCT04117932 | November 1, 2019 | 22 October 2019 | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Ustekinumab | CHU de Reims | Not recruiting | 18 Years | 90 Years | All | 18 | Phase 2 | France | |
| 3 | NCT03295383 | July 11, 2019 | 4 November 2019 | Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | Severe Forms of Mucous Membrane Pemphigoid | Drug: Rituximab 1g IV;Drug: Cyclophosphamide 50Mg Oral Tablet;Drug: Placebo of Rituximab;Drug: Placebo Oral Tablet | University Hospital, Rouen | Recruiting | 18 Years | 80 Years | All | 130 | Phase 3 | France | |
| 4 | NCT03926377 | April 2019 | 6 May 2019 | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Osteoporosis;Bullous Pemphigoid | Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate | Centre Hospitalier Universitaire, Amiens | University Hospital, Rouen | Not recruiting | 18 Years | N/A | All | 50 | Phase 4 | |
| 5 | NCT04035733 | September 25, 2018 | 4 November 2019 | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Bullous Pemphigoid (BP) | Biological: rVA576 | AKARI Therapeutics | Recruiting | 18 Years | N/A | All | 9 | Phase 2 | Germany;Netherlands | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03636763 | September 2018 | 27 August 2018 | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland | Bullous Pemphigoid | Drug: data report | Assistance Publique Hopitaux De Marseille | Recruiting | N/A | N/A | All | 183 | Phase 1 | France | |
| 7 | EUCTR2017-002836-18-NL | 07/05/2018 | 28 February 2019 | A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters) | A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | Mild to Moderate Bullous Pemphigoid MedDRA version: 20.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: rVA576 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: rVA576 Current Sponsor code: rVA576 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- | Akari Therapeutics Plc. | Authorised | Female: yes Male: yes | 9 | Phase 2 | Germany;Netherlands | |||
| 8 | JPRN-jRCTs051180069 | 12/04/2018 | 2 April 2019 | Imatinib treatment of autoimmune bullous diseases | Intervention study on autoimmune bullous diseases with imatinib - IABD | Autoimmune bullous disease including pemphigus group and pemphigoid group;D012872 | Imatinib 800 mg a day p.o. for seven days will be started within 14 days of starting steroid therapy (and when the bed is secured). | Kenji Kabashima | Takashi Nomura;Akihiko Kitoh;Tetsuya Honda;Gyohei Egawa;Yuichiro Endo;Yo Kaku;Atsushi Otsuka | Recruiting | 20 years old | One hundred years old | Both | 10 | Phase 0 | none |
| 9 | NCT03286582 | September 5, 2017 | 30 September 2019 | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid | A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid | Bullous Pemphigoid | Drug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical Ointment | TWi Biotechnology, Inc. | Not recruiting | 20 Years | 90 Years | All | 10 | Phase 2 | Taiwan | |
| 10 | NCT03099538 | August 15, 2017 | 26 August 2019 | Ixekizumab in the Treatment of Bullous Pemphigoid | Ixekizumab in the Treatment of Bullous Pemphigoid | Bullous Pemphigoid;Pemphigoid | Drug: Ixekizumab | Mayo Clinic | Eli Lilly and Company | Not recruiting | 18 Years | N/A | All | 6 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02993133 | December 2016 | 6 May 2019 | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Autoimmune Bullous Dermatose | Drug: Cellcept® in autoimmune bullous dermatoses | University Hospital, Limoges | Not recruiting | 18 Years | N/A | All | 53 | Phase 3 | France | |
| 12 | NCT02226146 | February 2016 | 11 June 2018 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid | Pemphigoid, Bullous | Biological: Bertilimumab | Immune Pharmaceuticals | Not recruiting | 60 Years | N/A | All | 11 | Phase 2 | United States;Israel | |
| 13 | NCT02874079 | December 2015 | 17 October 2016 | Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid | Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid | Bullous Pemphigoid | Other: Blood sample and cotton skin swabs | CHU de Reims | Recruiting | 18 Years | N/A | Both | 100 | N/A | France | |
| 14 | NCT02502903 | June 2015 | 4 November 2019 | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. | Bullous Pemphigoid (BP);Cold Agglutinin Disease (CAD);Warm Autoimmune Hemolytic Anemia (WAIHA);End-stage Renal Disease (ESRD) | Drug: BIV009;Other: Placebo | Bioverativ Therapeutics Inc. | Celerion Clinical Research GmbH;Assign Data Management and Biostatistics GmbH;ABF Pharmaceutical Services GmbH;Quest Diagnostics;Covance Laboratories - Chantilly | Recruiting | 18 Years | N/A | All | 122 | Phase 1 | Austria |
| 15 | NCT02360202 | April 2015 | 16 December 2017 | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Procedure: Impedance analysis;Drug: Clobetasol Propionate cream treatment | University Hospital, Rouen | Société de Dermatologie Française | Recruiting | 18 Years | N/A | All | 35 | Phase 4 | France |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02365675 | January 2015 | 2 March 2015 | Wound Dressings for Pemphigus and Pemphigoid | An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid | Pemphigus;Pemphigoid | Device: Cotton gauze with petrolatum;Device: Cellulose acetate with petrolatum;Device: Nanocrystalline silver (Acticoat);Device: Carboxymethylcellulose with ionic silver (Aquacel Ag) | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Recruiting | 18 Years | N/A | Both | 12 | N/A | Mexico |
| 17 | JPRN-UMIN000015451 | 2014/11/13 | 2 April 2019 | Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin. Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2 | Pemphigus, Pemphigoid | Rituximab 375mg/sqm, q1w, 4 doses. Maintenance administration of rituximab is possible if PDA or BPDAI is between 1 and 10 on week 24 to 48 | Department of Dermatology, Keio University School of Medicine | Hokkaido University, Kurume University, Okayama University, Kawasaki Medical School | Not Recruiting | 20years-old | 80years-old | Male and Female | 20 | Phase 1,2 | Japan | |
| 18 | NCT02126020 | November 2014 | 16 December 2017 | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid | Drug: topical infliximab | James Chodosh, MD, MPH | Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM) | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 1/Phase 2 | United States;Canada |
| 19 | JPRN-jRCTs031180220 | 01/05/2014 | 22 July 2019 | Rituximab treatment of blistering disease | Treatment of refractory autoimmuno blistering disease with rituximab | Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid | Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner. | Miwa Kanaoka | Aihara Michiko | Recruiting | 20 age old | 80 age old | Both | 10 | N/A | none |
| 20 | NCT02149732 | May 2014 | 2 May 2016 | Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation | An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients | Limbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical Burn | Biological: cultivated oral mucosal epithelial sheet transplantation | Seoul National University Hospital | Ministry of Health & Welfare, Korea | Not recruiting | 16 Years | N/A | Both | Phase 1/Phase 2 | Korea, Republic of | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | JPRN-UMIN000002948 | 2013/04/01 | 2 April 2019 | Cultivated epithelial sheet transplantation for corneal epithelial stem cell deficiency | a) Steven's Johnson Syndrome b) Ocular cicatricial pemphigoid c) Chemical/ Thermal Burns of the Cornea d) Gelatinous Drop Like Dystrophy e) Salzmann Corneal Degeneration f) Congenital Aniridia | Corneal epithelial sheet transplantation Cultivated eptihealial sheet transplantation will be perfored in the surgical department of Keio University Hospital. Simultaneous lamellar keratoplasty will be allowed. Surgical procedure involves removal of all pannus and abnormal epithelial tissue, the use of 0.04% mitomycin C to prevent fibrosis, and transplantation of the cultivated sheet. | Department of Ophthalmology, Keio University School of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 5 | Not selected | Japan | ||
| 22 | NCT02837965 | April 2013 | 8 August 2016 | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid | Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid | Bullous Pemphigoid | Drug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline) | CHU de Reims | Recruiting | 18 Years | N/A | Both | 150 | N/A | France | |
| 23 | EUCTR2011-004361-32-DE | 26/02/2013 | 11 April 2016 | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEM | Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions. ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Simvastatin-ratiopharm® Product Name: Simvastatin-ratiopharm Pharmaceutical Form: Capsule CAS Number: 79902-63-9 Other descriptive name: SIMVASTATIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Philipps-Universität Marburg | Not Recruiting | Female: yes Male: yes | Germany | |||||
| 24 | NCT01705795 | February 13, 2013 | 16 December 2017 | Anti-IL-5 Therapy in Bullous Pemphigoid (BP) | Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. | Pemphigoid, Bullous | Drug: Mepolizumab (a-IL-5 antibody);Drug: Placebo | University Hospital Inselspital, Berne | Not recruiting | 18 Years | N/A | All | 32 | Phase 2 | Switzerland | |
| 25 | NCT01688882 | January 2013 | 19 October 2017 | Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment | A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment | Bullous Pemphigoid | Drug: QGE031;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 20 Years | 80 Years | All | 20 | Phase 2 | United States;Austria;France;Germany;Japan;Taiwan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | EUCTR2012-003370-10-AT | 13/11/2012 | 10 July 2015 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | Refractory Bullous Pemphigoid MedDRA version: 15.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 Pharmaceutical Form: Concentrate for solution for injection/infusion Current Sponsor code: QGE031 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Concentrate for solution for injection/infusion Route of administration of the placebo: Subcutaneous use | Novartis Pharma AG | Not Recruiting | Female: yes Male: yes | 42 | United States;Taiwan;Austria;Germany | ||||
| 27 | NCT01582880 | March 2012 | 4 November 2019 | Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis | The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis | Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases | Drug: Riboflavin | Joseph B. Ciolino, MD | Not recruiting | 18 Years | N/A | All | 1 | Phase 1/Phase 2 | United States | |
| 28 | NCT02202642 | January 2012 | 19 February 2015 | The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells | The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells | Alkaline Chemical Burn Of Cornea And Conjunctival Sac;Acid Chemical Burn Of Cornea And Conjunctival Sac;Benign Mucous Membrane Pemphigoid With Ocular Involvement | Procedure: collagenase | National Taiwan University Hospital | Recruiting | 18 Years | 70 Years | Both | 10 | Phase 1 | Taiwan | |
| 29 | ChiCTR-TRC-12003538 | 2011-08-01 | 18 April 2017 | Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology, Chinese Academy of Medical Sciences | Recruiting | 18 | 0 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | Post-market | China | |
| 30 | ChiCTR-TRC-12003592 | 2011-08-01 | 18 April 2017 | Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Tripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.; | Institute of dermatology, Chinese Academy of Medical Sciences | Not Recruiting | 18 | Both | Tripterygium glycosides group:100;Nicotinamide plus Minocycline group:100; | Post-market | China | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | ChiCTR-TRC-12003593 | 2011-08-01 | 18 April 2017 | Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology; Chinese Academy of Medical Sciences | Not Recruiting | 18 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | Post-market | China | ||
| 32 | NCT01408550 | August 2011 | 19 February 2015 | Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III) | Bullous Pemphigoid | Drug: NPB-01;Drug: Placebo | Nihon Pharmaceutical Co., Ltd | Not recruiting | 20 Years | N/A | Both | 56 | Phase 3 | Japan | |
| 33 | EUCTR2011-000756-42-DE | 15 July 2013 | Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in patients with active bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: not applicable Product Code: DF2156A Pharmaceutical Form: Capsule, hard INN or Proposed INN: ladarixin CAS Number: 865625-56-5 Current Sponsor code: DF2156A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- | Dompé s.p.a. | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy | ||||
| 34 | JPRN-UMIN000004428 | 2010/11/01 | 2 April 2019 | Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita. | pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita | Rituximab | Research group of rare intractable dermatologial disorder | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Phase 2 | Japan | ||
| 35 | ChiCTR-IOR-15007146 | 2009-10-01 | 18 April 2017 | Combined treatment with low dose systemic steroids andtopical steroids in bullous pemphigoid andfactors of treatment-refractory bullous pemphigoid | Efficacy of low dose systemic steroids combined with topical steroids in the treatment of bullous pemphigoid andrisk factors for treatment-refractory patients:A Randomized Controlled Trial | bullous pemphigoid | Control Group (C):apply 0.05% halometasone cream daily;Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids; | Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine | Not Recruiting | Both | Control Group (C):40;Treatment Group (T):40; | Other | China | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2007-006658-24-GB | 05/03/2009 | 19 March 2012 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 14.0 Level: LLT Classification code 10006568 Term: Bullous pemphigoid NOS System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | Product Name: prednisolone Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone CAS Number: 50-24-8 Product Name: doxycycline Pharmaceutical Form: Capsule INN or Proposed INN: doxycycline CAS Number: 50-24-8 Product Name: prednisolone Pharmaceutical Form: Soluble tablet INN or Proposed INN: prednisolone CAS Number: 50-24-8 Product Name: prednisolone Pharmaceutical Form: Coated tablet INN or Proposed INN: prednisolone CAS Number: 50-24-8 Product Name: doxycycline Pharmaceutical Form: Dispersible tablet INN or Proposed INN: doxycycline CAS Number: 50-24-8 | University of Nottingham | Authorised | Female: yes Male: yes | 256 | Germany;United Kingdom | ||||
| 37 | EUCTR2008-005266-31-FR | 06/02/2009 | 19 March 2012 | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | Pemphogoide bulleuse MedDRA version: 9.1 Level: LLT Classification code 10006567 Term: Bullous pemphigoid | Trade Name: mabthéra Product Name: mathéra Pharmaceutical Form: Solution for injection Trade Name: Prednisone Product Name: CORTANCYL 20 mg Pharmaceutical Form: Tablet | CHU-Hôpitaux de Rouen | Authorised | Female: yes Male: yes | France | |||||
| 38 | NCT00525616 | December 2008 | 19 February 2015 | Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid | Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid. | Bullous Pemphigoid | Drug: Mabthera | University Hospital, Rouen | Not recruiting | 18 Years | 80 Years | Both | 18 | Phase 3 | France | |
| 39 | NCT00809822 | November 2008 | 19 February 2015 | Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase?). | Bullous Pemphigoid | Drug: NPB-01;Drug: Placebo | Nihon Pharmaceutical Co., Ltd | Not recruiting | 20 Years | N/A | Both | 20 | Phase 2 | Japan | |
| 40 | EUCTR2008-000480-41-IT | 27/05/2008 | 19 March 2012 | Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid. - ND | Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid. - ND | Ocular cicatricial pemphigoid (OCP) MedDRA version: 9.1 Level: LLT Classification code 10010746 Term: Conjunctivitis chronic | Trade Name: RESTASIS Pharmaceutical Form: Eye drops, suspension INN or Proposed INN: Cyclosporine Concentration unit: % percent Concentration type: equal Concentration number: .05- Pharmaceutical form of the placebo: Eye drops, suspension Route of administration of the placebo: Ocular use | UNIVERSITA' CAMPUS BIOMEDICO | Authorised | Female: yes Male: yes | Italy | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT02313870 | January 2008 | 19 February 2015 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid | Bullous Pemphigoid | Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone | University Hospital, Montpellier | Recruiting | 18 Years | N/A | Both | 300 | Phase 3 | France | |
| 42 | EUCTR2007-003545-32-FR | 14/09/2007 | 19 March 2012 | Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABUL | Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABUL | Pemphigoïde bulleuse MedDRA version: 9.1 Level: LLT Classification code 10006567 Term: Bullous pemphigoid | Trade Name: ARAVA Pharmaceutical Form: Tablet Trade Name: DERMOVAL Pharmaceutical Form: Cream | CHU de Limoges | Authorised | Female: yes Male: yes | France | |||||
| 43 | NCT00472030 | August 2007 | 19 October 2017 | Efficacy and Safety of Omalizumab in Bullous Pemphigoid | An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Omalizumab;Drug: prednisone | University of Iowa | Genentech, Inc. | Not recruiting | 18 Years | N/A | All | 2 | Phase 4 | United States |
| 44 | NCT00584935 | January 2006 | 16 December 2017 | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Ocular Cicatricial Pemphigoid | Drug: Rituximab | University of Alabama at Birmingham | Genentech, Inc.;Biogen | Not recruiting | 19 Years | N/A | All | 3 | Phase 1/Phase 2 | United States |
| 45 | EUCTR2005-001827-12-DE | 29/12/2005 | 19 March 2012 | Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie | Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie | Bullous Pemphigoid | Trade Name: Myfortic 180 mg Product Name: Myfortic 180 mg Filmtabletten Pharmaceutical Form: Film-coated tablet | Georg-August-Universität Göttingen, Bereich Humanmedizin | Authorised | Female: yes Male: yes | 10 | Germany | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | EUCTR2005-002391-14-GB | 29/09/2005 | 18 April 2012 | Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid | Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid | ocular mucous membrane pemphigoid | Trade Name: Solu-Medrone Pharmaceutical Form: Powder for infusion* Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Moorfields Eye Hospital NHS Foundation Trust | Authorised | Female: yes Male: yes | 20 | United Kingdom | ||||
| 47 | NCT00286325 | March 2005 | 19 October 2017 | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab | Duke University | Genentech, Inc. | Not recruiting | 18 Years | N/A | All | 8 | Phase 1/Phase 2 | United States |
| 48 | NCT00213421 | August 2001 | 19 February 2015 | Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus | Bullous Pemphigoid | Drug: Dermoval | University Hospital, Rouen | Not recruiting | 18 Years | N/A | Both | 330 | Phase 4 | France | ||
| 49 | NCT00431119 | October 1997 | 19 February 2015 | Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid | A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid | Bullous Pemphigoid | Drug: Azathioprine or Mycophenolate mofetil | University Hospital Muenster | Hoffmann-La Roche | Not recruiting | 18 Years | 90 Years | Both | 70 | Phase 2 | Germany |